Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2

EMBO Journal

Volumn 18, Issue 7, 1999, Pages 1805-1814

  Unger, Tamar ^c   Juven Gershon, Tamar ^c   Moallem, Eli ^a   Berger, Michael ^a   Vogt Sionov, Ronit ^a   Lozano, Guillermina ^b   Oren, Moshe ^c   Haupt, Ygal ^a  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF TEXAS   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apoptosis; Degradation; Mdm2; p53; Phosphorylation

Indexed keywords

ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN P53; SERINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOREGULATION; CONTROLLED STUDY; FEEDBACK SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION;

ANIMALIA; MURINAE;

EID: 0033119627     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/18.7.1805     Document Type: Article

References (76)

1. cdc2 kinase motif. Oncogene, 5, 423-426.
2. Agarwal, M.L., Taylor, W.R., Chernov, M.V., Chernova, O.B. and Stark, G.R. (1998) The p53 network. J. Biol. Chem., 273, 1-4.
3. Banin, S. et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science, 281, 1674-1677.
4. Barak, Y., Gottlieb, E., Juven Gershon, T. and Oren, M. (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev., 8, 1739-1749.
5. Baudier, J., Delphin, C., Grunwald, D., Khochbin, S. and Lawrence, J.J. (1992) Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc. Natl Acad. Sci. USA, 89, 11627-11631.
6. Bischoff, J.R., Friedman, P.N., Marshak, D.R., Prives, C. and Beach, D. (1990) Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl Acad. Sci. USA, 87, 4766-4770.
7. Böttger, A., Böttger, V., Sparks, A., Liu, W.L., Howard, S.F. and Lane, D.P. (1997) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol., 7, 860-869.
8. Buckbinder, L., Talbott, R., Velasco Miguel, S., Takenaka, I., Faha, B., Seizinger, B.R. and Kley, N. (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature, 377, 646-649.
9. Canman, C.E., Lim, D.-S., Cimprich, K.A., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M.B. and Siliciano, J.D. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science, 281, 1677-1679.
10. Chen, J., Lin, J. and Levine, A.J. (1995) Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med., 1, 142-152.
11. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol., 16, 2445-2452.
12. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M.A., Lassota, P. and Traganos, F. (1992) Features of apoptotic cells measured by flow cytometry. Cytometry, 13, 795-808.
13. ARF tumor suppressor. Genes Dev. 12, 2434-2442.
14. El-Deiry, W.S. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell. 75, 817-825.
15. Fiscella, M., Zambrano, N., Ullrich, S.J., Unger, T., Lin, D., Cho, B., Mercer, W.E., Anderson, C.W. and Appella, E. (1994) The carboxy-terminal serine-392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene, 9, 3249-3257.
16. Fuchs, S.Y., Fried, V. and Ronai, Z. (1998a) Stress-activated kinases regulate protein stability. Oncogene, 17, 1483-1490.
17. Fuchs, S.Y, Alder, V., Buschmann, T., Yin, Z., Wu, X., Jones, S.N. and Ronai, Z. (1998b) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev., 12, 2658-2663.
18. Giaccia, A.J. and Kastan, M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 12, 2973-2983.
19. Gottlieb, T.M. and Oren, M. (1996) p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1287, 77-102.
20. Grossman, S.R., Perez, M., Kung, A.L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howely, P.M. and Livingston, D.M. (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell, 2, 405-415.
21. Hao, M., Lowy, A.M., Kapoor, M., Deffie, A., Liu, G. and Lozano, G. (1996) Mutation of phosphoserine 389 affects p53 function in vivo. J. Biol. Chem., 271, 29380-29385.
22. Haupt, Y., Barak, Y. and Oren, M. (1996) Cell type-specific inhibition of p53-mediated apoptosis by Mdm2. EMBO J., 15, 1596-1606.
23. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-299.
24. 2/M progression. Mol. Cell, 1, 3-11.
25. Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420, 25-27.
26. 1 arrest. Proc. Natl Acad. Sci. USA, 93, 4827-4832.
27. Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992) Regulation of the specific DNA binding function of p53. Cell, 71, 875-886.
28. Jamal, S. and Ziff, E.B. (1995) Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene, 10, 2095-2101.
29. Jones, S.N., Roe, A.E., Donehower, L.A. and Bradley, A. (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature, 378, 206-208.
30. Kapoor, M. and Lozano, G. (1998) Functional activation of p53 via phosphorylation following DNA damage by UV but not γ radiation. Proc. Natl Acad. Sci. USA, 95, 2834-2837.
31. Kubbutat, M.H.G., Jones, S.N. and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature, 387, 299-303.
32. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J. and Pavletich, N.P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953.
33. Lees-Miller, S.P., Sakaguchi, K., Ullrich, S.J., Appella, E. and Anderson, C.W. (1992) Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol., 12, 5041-5049.
34. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
35. Lozano, G. and Montes de Oca Luna, R. (1998) MDM2 function. Biochim. Biophys. Acta, 1377, M55-M59.
36. Lu, H. and Levine, A.J. (1995) Human TAF (II)31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl Acad. Sci. USA, 92, 5154-5158.
37. Lu, H., Fisher, R.P. Bailey, P. and Levine, A.J. (1997) The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol. Cell. Biol., 17, 5923-5934.
38. Lu, H., Taya, Y., Ikeda, M. and Levine, A.J. (1998) Ultraviolet radiation. but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl Acad. Sci. USA, 95, 6399-6402.
39. Mayo, L.D., Turchi, J.J. and Berberich, S.J. (1997) Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res., 57, 5013-5016.
40. McMasters, K.M., Montes de Oca Luna, R., Pena, J.R. and Lozanu, G. (1996) mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene, 13, 1731-1736.
41. Meek, D.W. (1998) Multisite phosphorylation and the integration of stress signals at p53. Cell Signal, 10, 159-166.
42. Meek, D.W., Simon, S., Kikkawa, U. and Eckhart, W. (1990) The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II, EMBO J., 9, 3253-3260.
43. Midgley, C.A. and Lane, D.P. (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene, 15, 1179-1189.
44. Milczarek, G.J., Martinez, J. and Bowden, G.T. (1997) p53 phosphorylation: biochemical and functional consequences. Life Sci., 60, 1-11.
45. Milne, D.M., Palmer, R.H., Campbell, D.G. and Meek, D.W. (1992) Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene, 7, 1361-1369.
46. Milne, D.M., Campbell, L.E., Campbell, D.G. and Meek, D.W. (1995) p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J. Biol. Chem., 270, 5511-5518.
47. Miyashita, T. and Reed, J.C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-299.
48. Momand, J. and Zambetti, G.P. (1997) Mdm-2: 'big brother' of p53. J. Cell. Biochem., 64, 343-352.
49. Montes de Oca Luna, R., Wagner, D.S. and Lozano, G. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 378, 203-206.
50. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W. and Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-860.
51. Owen-Schaub, L.B. et al. (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15, 3032-3040.
52. Picksley, S.M., Vojtesek, B., Sparks, A. and Lane, D.P. (1994) Immunochemical analysis of the interaction of p53 with MDM2; line mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene, 9, 2523-2529.
53. Piette, J., Neel, H. and Marechal, V. (1997) Mdm2: keeping p53 under control. Oncogene, 15, 1001-1010.
54. Polyak, K., Xia, Y. Zweier, J.L., Kinzler, K.W. and Vogelstein, B. (1997) A model for p53-induced apoptosis. Nature, 389, 300-305.
55. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92, 713-723.
56. Price, B.D., Hughes Davies, L. and Park, S.J. (1995) Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene, 11, 73-80.
57. Prives, C. (1998) Signaling to p53: breaking the Mdm2-p53 circuit. Cell, 95, 5-8.
58. Renzing, J. and Lane, D.P. (1995) p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene, 10, 1865-1868.
59. Roth, J., Dobhelstein, M., Freedman, D.A., Shenk, T. and Levine, A.J. (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17, 554-564.
60. Sakaguchi, K., Herrera, J.E., Siato, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C.W. and Appella, E. (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 12, 2831-2841.
61. Shieh, S.-Y. Ikeda, M., Taya, Y. and Prives, C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91, 325-334.
62. Shieh, S.-Y., Taya, Y. and Prives, C. (1999) DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20. requires tetramerization. EMBO J., 18, 1815-1823.
63. Siliciano, J.D., Canman, C.E., Taya, Y. Sakaguchi, K., Appella, E. and Kastan, M.B. (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev., 11, 3471-3481.
64. Steegenga, W.T., van der Eb, A.J. and Jochemsen, A.G. (1996) How phosphorylation regulates the activity of p53. J. Mol. Biol., 263, 103-113.
65. Takenaka, I., Morin, F. Seizinger, B.R. and Kley, N. (1995) Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem., 270, 5405-5411.
66. Thomas, A. and White, E. (1998) Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. Genes Dev., 12, 1975-1985.
67. Unger, T., Nau, M.M., Segal, S. and Minna, J.D. (1992) p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J., 11, 1383-1390.
68. Unger, T., Mietz J.A., Scheffner, M., Yee, C.L. and Howley, P.M. (1993) Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition and transformation suppression. Mol. Cell. Biol., 13, 5186-5194.
69. Unger, T., Vogt Sionov, R., Moallem, E., Yee, C.L., Howley, P.M., Oren, M. and Haupt, Y. (1999) Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene (in press).
70. Velculescu, V.E. and El-Deiry, W.S. (1996) Biological and clinical importance of the p53 tumor suppressor gene. Clin. Chem., 42, 858-868.
71. 1 cyclin-dependent kinases. Nature, 376, 88-91.
72. Waterman, M.J.F. Stavridi, E.S., Waterman, J.L.F. and Halazonetis, T.D. (1998) ATM-dependent activation of p53 involves dephophorylation and association with 14-3-3 proteins. Nature Genet., 19, 175-178.
73. Woo, R.A., McLure, K.G., Lees-Miller, S.P., Rancourt, D.E. and Lee, P.W.K. (1998) DNA-dependem protein kinase acts upstream of p53 in response to DNA damage. Nature, 394, 700-704.
74. Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y. and Oren, M. (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res., 23, 2584-2592.
75. Zhang, Y., Xiong, Y. and Yarbrough, W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92, 725-734.
76. Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J. and Roussel, M.F. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev., 12, 2424-2433.